Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials

Autor: Langley, Rg, Elewski, Be, Lebwohl, M, Reich, K, Griffiths, Ce, Papp, K, Puig, L, Nakagawa, H, Spelman, L, Sigurgeirsson, B, Rivas, E, Tsai, Tf, Wasel, N, Tyring, S, Salko, T, Hampele, I, Notter, M, Karpov, A, Helou, S, Papavassilis, C, ERASURE Study Group, FIXTURE Study Group, Potenza, C

Publikováno v: NEW ENGLAND JOURNAL OF MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb51c97b974b7131f9b8ec73a2c0220c
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9201